Abstract
Vaccine strategies aimed at enhancing the processing of tumor antigens by activated 'professional' antigen presenting cells (APCs) can sometimes result in the generation of systemic T-cell mediated anti-tumor immune responses capable of eradicating a micrometastatic tumor burden. This observation raises the interesting question of why certain tumors such as B-cell lymphomas or myeloid leukemias malignancies in lineages normally characterized by potent APC capacity - fail to be eliminated by host T-cell responses. Potentially unique aspects of the immune response to such hematopoietic cancers are discussed in the context of the current understanding of factors regulating T-cell activation and tolerance. These considerations may have relevance for the application of cancer immunotherapy to this class of diseases.
Original language | English (US) |
---|---|
Pages (from-to) | 281-287 |
Number of pages | 7 |
Journal | Seminars in Immunology |
Volume | 8 |
Issue number | 5 |
DOIs | |
State | Published - Oct 1996 |
Keywords
- Antigen presenting cell
- Antigen processing
- Hematologic malignancies
- Lymphoma
- Tolerance
ASJC Scopus subject areas
- Immunology and Allergy
- Infectious Diseases
- Immunology